Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.

Protective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A9...

Full description

Bibliographic Details
Main Authors: Susana Martiñón, Elisa García, Gabriel Gutierrez-Ospina, Humberto Mestre, Antonio Ibarra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3279414?pdf=render
id doaj-16c876e6e5d449fcb7342f1a91a1c224
record_format Article
spelling doaj-16c876e6e5d449fcb7342f1a91a1c2242020-11-24T21:34:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3202710.1371/journal.pone.0032027Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.Susana MartiñónElisa GarcíaGabriel Gutierrez-OspinaHumberto MestreAntonio IbarraProtective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A91. Immunizing with A91 has shown to promote neuroprotection after SCI and its use has proven to be feasible in a clinical setting. The broad applications of neural-derived peptides make it important to determine the main features of this anti-A91 response. For this purpose, adult Sprague-Dawley rats were subjected to a spinal cord contusion (SCC; moderate or severe) or a spinal cord transection (SCT; complete or incomplete). Immediately after injury, animals were immunized with PBS or A91. Motor recovery, T cell-specific response against A91 and the levels of IL-4, IFN-γ and brain-derived neurotrophic factor (BDNF) released by A91-specific T (T(A91)) cells were evaluated. Rats with moderate SCC, presented a better motor recovery after A91 immunization. Animals with moderate SCC or incomplete SCT showed significant T cell proliferation against A91 that was characterized chiefly by the predominant production of IL-4 and the release of BDNF. In contrast, immunization with A91 did not promote a better motor recovery in animals with severe SCC or complete SCT. In fact, T cell proliferation against A91 was diminished in these animals. The present results suggest that the effective development of PA and, consequently, the beneficial effects of immunizing with A91 significantly depend on the severity of SCI. This could mainly be attributed to the lack of T(A91) cells which predominantly showed to have a Th2 phenotype capable of producing BDNF, further promoting neuroprotection.http://europepmc.org/articles/PMC3279414?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Susana Martiñón
Elisa García
Gabriel Gutierrez-Ospina
Humberto Mestre
Antonio Ibarra
spellingShingle Susana Martiñón
Elisa García
Gabriel Gutierrez-Ospina
Humberto Mestre
Antonio Ibarra
Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
PLoS ONE
author_facet Susana Martiñón
Elisa García
Gabriel Gutierrez-Ospina
Humberto Mestre
Antonio Ibarra
author_sort Susana Martiñón
title Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
title_short Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
title_full Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
title_fullStr Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
title_full_unstemmed Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
title_sort development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Protective autoimmunity (PA) is a physiological response to central nervous system trauma that has demonstrated to promote neuroprotection after spinal cord injury (SCI). To reach its beneficial effect, PA should be boosted by immunizing with neural constituents or neural-derived peptides such as A91. Immunizing with A91 has shown to promote neuroprotection after SCI and its use has proven to be feasible in a clinical setting. The broad applications of neural-derived peptides make it important to determine the main features of this anti-A91 response. For this purpose, adult Sprague-Dawley rats were subjected to a spinal cord contusion (SCC; moderate or severe) or a spinal cord transection (SCT; complete or incomplete). Immediately after injury, animals were immunized with PBS or A91. Motor recovery, T cell-specific response against A91 and the levels of IL-4, IFN-γ and brain-derived neurotrophic factor (BDNF) released by A91-specific T (T(A91)) cells were evaluated. Rats with moderate SCC, presented a better motor recovery after A91 immunization. Animals with moderate SCC or incomplete SCT showed significant T cell proliferation against A91 that was characterized chiefly by the predominant production of IL-4 and the release of BDNF. In contrast, immunization with A91 did not promote a better motor recovery in animals with severe SCC or complete SCT. In fact, T cell proliferation against A91 was diminished in these animals. The present results suggest that the effective development of PA and, consequently, the beneficial effects of immunizing with A91 significantly depend on the severity of SCI. This could mainly be attributed to the lack of T(A91) cells which predominantly showed to have a Th2 phenotype capable of producing BDNF, further promoting neuroprotection.
url http://europepmc.org/articles/PMC3279414?pdf=render
work_keys_str_mv AT susanamartinon developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury
AT elisagarcia developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury
AT gabrielgutierrezospina developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury
AT humbertomestre developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury
AT antonioibarra developmentofprotectiveautoimmunitybyimmunizationwithaneuralderivedpeptideisineffectiveinseverespinalcordinjury
_version_ 1725948725679882240